Lymeseek, a Diagnostic Test Combing Multiple Blood Biomarsers and a Machine Learning Algorithm, has shown over 90% Accuration in Diagnosis Lyme Disease Across All Stages, Including the Early Phases when Current Tests often Fail to Identify the Inference. Aces Diagnostics, The Companes Behind ITS Development, Expects The Blood Test to Be Commercially Available by the End of 2026.
Lyme Disease is a tick-borne Disease that Affects 475,000 People in the Us Every Year. Where caught early, with the first weeks of information, The Condition Can offen Be Effectively Treated with Antibiotics. Howver, Diagnosis in this early status haas long prove a challenge, with many patiences recepting a Diagnosis Months or Even Years after Information. This can have dire consequences, SINCE MERE THAN HALF Of Patiences Not Diagnosis or Treated With that First Two-Wind Wind Will Develop Long-time Fatigue, Anthritis, and Neurology Symptoms.
Two-Tier Serology is the Current Diagnostic Standard for Lyme Disease, an approach consisting of an imhanoassay Test to delteect a general antibody response Followed by a more speecificic Test to Identify Antibodies Against the Bacteria Causing Lyme Disease. This Type of Test Has Less Than 50% Accuration Overall, and Lower Than 30% Accuration in the earls of Lyme Disease, Leaving Many Indiesals at Risk of Not Receiving Prumpt Treatment and Developing Chronic symptoms.
In card In a study in human body samples, Including 123 Samples of Lyme Disease and 197 of UninfCted Individuals, Lymeseek Showed Over 90% Sensitive and Specificity Across All Disease Stages. Detailing Results Will Be Presented at the Association for Diagnostics & Laboratory Medicine (ADLM) 2025Taking Place this Week in Chicago.
“Nine Out of 10 Patients are Going to Get a Correct Diagnosis and Receive AppropriaTE Treatment, Whiche Lowers the Risk of Chronic Illung Signicantly,” Said Holly a ceren, MS, MT, Professor of Microbiology at the State University of New York, Chief Scientific Office at Actions Diagnostics, and Scientific Advisor for the Focus on Lyme Foundation.
Amber’s Own Daughter Strugled For Years with Disableing Symptoms from Lyme Disease that el -Been Prevented with an early Diagnosis. This Experience, Whiche Was shared by Aces Diagnostics Co-Founder and Chief Executive Office Tammy Crawford, Motivated the Two Women to Take Action Against the Lack of Accorate And Accessible Diagnostic Tests for Lyme Disease.
The use of a Machine learning Algorithm to Detect Unique Immune Patterns in Each Sample is One of the Key Elements Enables The High Acquiry of this Test. “You and I Might Get Infected by the Same Bacteria, but we might Both Produce different antibody responses to it,” said a ceren. “With these Antigens MATICED With a Decision-Tree-Based Classifier, We Can ACTually Pick that Up in Each Individual Case.”
Such a Significant Increase in Accuration Coup Make a HUGE Difference to Pations at Earlier Stages of Lyme Disease, where the Information is Still Curable and can be more levelly Treated. In Addition, The Test is Experted to Be Inexpeensive and Work on Standard Equipment Found in Clinical Laboratories, make it US More Accessible in a Diagnostic Setting.
